A novel patient-derived xenograft model for claudin-low triple-negative breast cancer.

ABSTRACT: BACKGROUND:Triple-negative breast cancer (TNBC) subtypes are clinically aggressive and cannot be treated with targeted therapeutics commonly used in other breast cancer subtypes. The claudin-low (CL) molecular subtype of TNBC has high rates of metastases, chemoresistance and recurrence. There exists an urgent need to identify novel therapeutic targets in TNBC; however, existing models utilized in target discovery research are limited. Patient-derived xenograft (PDX) models have emerged as superior models for target discovery experiments because they recapitulate features of patient tumors that are limited by cell-line derived xenograft methods. METHODS:We utilize immunohistochemistry, qRT-PCR and Western Blot to visualize tumor architecture, cellular composition, genomic and protein expres

SUBMITTER: Matossian MD 

PROVIDER: S-EPMC5948145 | biostudies-literature | 2018 Jun

REPOSITORIES: biostudies-literature